ResearcherTaizhou Central HospitalNo recent work listed

Weidong Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-2526-7695; OpenAlex author ID A5048501577. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper

Papers 2

TLE2 is associated with favorable prognosis and regulates cell growth and gemcitabine sensitivity in pancreatic cancer. Last author DOI 10.21037/atm-20-5492 ↗
Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. Last author DOI 10.3892/ol.2017.7058 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shixiong Hu · 1 shared paper, 2020 · strength 0.13
- Paper TLE2 is associated with favorable prognosis and regulates cell growth and gemcitabine sensitivity in pancreatic cancer. DOI 10.21037/atm-20-5492 ↗
Jinggang Mo · 1 shared paper, 2017 · strength 0.07
- Paper Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. DOI 10.3892/ol.2017.7058 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.